Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Synthomer reports in line 1H trading, reiterates full-year guidance

(Sharecast News) - Synthomer reported growth in revenues, earnings and underlying earnings per share over the first half of 2024 and reiterated its full-year guidance. Nonetheless, whilst trading was in line with expectations, there was no evidence of a "sustained" increase in end-market demand.

"While we remain cautiously encouraged by trading in some end markets since the start of the year, evidence of a broad-based recovery in demand remains limited," Synthomer boss, Michael Willome, said.

"Despite this, we have made earnings progress by delivering on our cost and operational efficiency programmes, and we continue to strengthen our strategic positioning for the future by focusing on our speciality businesses, creatively managing our resources and enhancing our operating leverage."

Revenues for the six months ending on 30 June were ahead by 3.5% to £1.05bn at constant currencies.

Earnings before interest and tax meanwhile rose by 18.7% to £29.0m.

On an underlying basis, EPS came in at 1.3 after -8.0 in 2023.

The specialty chemicals manufacturer also said that it was on track to turn positive on free cash flow for the full-year and that it had extended its debt maturities.

Modest positive free cash flows were anticipated even without a broad-based improvement in demand.

Free cash flow over the latest six-month stretch was negative to the tune of £31.2m.

However, net debt shrank from £795.8m one year before to £560.6m.

At 4.7 times its EBITDA operating profit, net debt was "well within" the limits set out in its debt covenants, the company said.

Management also noted that it had refinanced a €350m bond with the next debt maturity in 2027.

Share this article

Related Sharecast Articles

PepsiCo cuts revenue outlook again
(Sharecast News) - PepsiCo cut its annual organic revenue guidance again on Tuesday as it highlighted a "subdued" performance in North America in the third quarter.
Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.